Although several biomarkers such as angiopoietin 2 and vascular endothelial growth factor have been proposed as predictors of survival in patients with advanced HCC [8], there are no consolidated biomarkers or molecular profiles of treatment efficacy nor HCC prognosis [2,9]. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.